Vivoryon Therapeutics: Leadership Expected at Key Investor Conference in April
Vivoryon Therapeutics N.V., a clinical-stage biotechnology company, announces its management's participation in an investor conference scheduled for April 2026. Listed on Euronext Amsterdam, the company continues its regular dialogue with shareholders and analysts.
Management Participation at the Conference
Vivoryon Therapeutics announces that Julia Neugebauer, PhD and Chief Operating Officer, will participate in the Van Lanschot Kempen Life Sciences Conference, which will be held in Amsterdam, Netherlands, on April 16, 2026. This participation is part of the company's ongoing dialogue with the investor community.
Focus on Innovative Drug Development
Vivoryon Therapeutics is a clinical-stage biotechnology company focused on the development of innovative small molecules for the treatment of inflammatory and fibrotic kidney disorders. The company's most advanced program, varoglutamstat, is an orally administered, first-in-class QPCT/L inhibitor, currently under evaluation for the treatment of diabetic nephropathy.
